“It’s a great day for Bioporto”
Diagnotics company Bioporto has submitted a registration application to the FDA for its important NGAL test in what the company’s CEO calls “a major milestone”.
BY BENJAMIN WERNER CHRISTENSEN
BioPorto has submitted a registration application to the US Food and Drug Administration, FDA, for approval of The NGAL Test. The submission is based on finalized data from the clinical study in the US that satisfactorily support the application’s claim regarding the use of The NGAL Test in the diagnosis of acute kidney injury.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Bioporto wants to build US organization
For abonnenter
BioPorto wraps up enrollment ahead of summer NDA
For abonnenter
BioPorto expects fast US penetration
For abonnenter
